References
- Turner MS, Drew RH, Perfect JR. Emerging echinocandins for treatment of invasive fungal infections. Expert Opin Emerg Drugs 2006;11:231-50
- Morris MI, Villmann M. Echinocandins in the management of invasive fungal infections, part 1. Am J Health Syst Pharm 2006;63:1693-703
- Cancidas package insert. Whitehouse Station, NJ, USA: Merck & Co, Inc., 2005
- McCormack PL, Perry CM. Caspofungin: a review of its use in the treatment of fungal infections. Drugs 2005;65:2049-68
- Mycamine package insert. Deerfield, IL, USA: Astellas Pharma US, Inc., 2008
- Eraxis package insert. New York, NY, USA: Pfizer, Inc., 2006
- Patterson TF, Kirkpatrick WR, Alexander B, et al. Efficacy and safety of caspofungin (CAS) in a real world clinical setting. Poster presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 17–20, 2007; Chicago, IL
- Ota Y, Tatsuno K, Okugawa S, et al. Relationship between the initial dose of micafungin and its efficacy in patients with candidemia. J Infect Chemother 2007;13:208-12
- Blanchette CM, Joshi AV, Szpalski M, et al. Comparison between spinal surgery blood transfusion services costs and associated treatment practices in the United States and Belgium. Curr Med Res Opin 2007;23:2793-804
- McQuellon RP, Russell GB, Shen P, et al. Survival and health outcomes after cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of appendiceal origin. Ann Surg Oncol 2008;15:125-33
- Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995;20:1526-30
- Pettengell K, Mynhardt J, Kluyts T, et al.; FK463 South African Study Group. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment Pharmacol Ther 2004;20:475-81